Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Insulin Lispro (Humalog) vs Kisspeptin-10
An educational, source-based comparison of Insulin Lispro (Humalog) and Kisspeptin-10 — how each peptide works, what it's researched for, and what to know before going deeper.
Recombinant insulin analog with reversed lysine and proline at B28/B29, reducing self-association so it acts within ~15 minutes for postprandial glucose control.
- Prandial coverage in T1D/T2D
- Insulin pump therapy
- Hyperglycemic crises (with caution)
- • FDA-approved.
- • Hypoglycemia risk if meal delayed or skipped.
A peptide product of the KISS1 gene that acts upstream of GnRH neurons via the KISS1R/GPR54 receptor. Research demonstrates robust LH (and indirectly testosterone/estradiol) responses without desensitizing the pituitary.
- Hypothalamic amenorrhea
- Male hypogonadism research
- IVF triggering protocols
- • Investigational; not FDA-approved.
- • Effects on the HPG axis warrant physician oversight.
Insulin Lispro (Humalog) vs Kisspeptin-10 — Key differences
- Class: Insulin Lispro (Humalog) is classified as Insulin Analog · Endocrine, while Kisspeptin-10 is Hormonal · HPG Axis.
- Primary research focus: Insulin Lispro (Humalog) — prandial coverage in t1d/t2d; Kisspeptin-10 — hypothalamic amenorrhea.
- Tag: FDA-Approved · Diabetes vs Hormonal · HPG axis.